| |
Infectious
|
Non-infectious
|
|---|
|
SHR
|
95% CI
|
P-value
|
SHR
|
95% CI
|
P-value
|
|---|
|
Univariate analysis
|
|
Group
|
|
Reduced dose rate group
|
1 (ref)
| | |
1 (ref)
| | |
|
Conventional dose rate group
|
1.77
|
0.81–3.85
|
0.153
|
4.06
|
0.90–18.28
|
0.068
|
|
Total dose (Gy)
|
1.38
|
1.02–1.87
|
0.038
|
0.83
|
0.55–1.26
|
0.381
|
|
Daily dose (Gy)
|
|
Daily dose < 3
|
1 (ref)
| | |
1 (ref)
| | |
|
Daily dose ≥3
|
0.52
|
0.25–1.10
|
0.087
|
0.68
|
0.37–1.22
|
0.201
|
|
Women
|
1.22
|
0.64–2.34
|
0.545
|
1.10
|
0.35–3.44
|
0.871
|
|
Age at TBI (year)
|
1.00
|
0.98–1.02
|
0.854
|
0.99
|
0.96–1.02
|
0.486
|
|
Cancer type
|
|
ALL
|
1 (ref)
| | |
1 (ref)
| | |
|
AML
|
1.69
|
0.87–3.31
|
0.124
|
1.40
|
0.30–6.57
|
0.668
|
|
Others
|
1.22
|
0.48–3.09
|
0.671
|
1.26
|
0.36–4.44
|
0.718
|
|
Unrelated donor
|
1.30
|
0.68–2.48
|
0.436
|
0.98
|
0.34–2.85
|
0.971
|
|
Conditioning regimen
|
|
Cyclophosphamide
|
1 (ref)
| | |
1 (ref)
| | |
|
Cyclophosphamide + other*
|
1.65
|
0.65–4.20
|
0.290
|
Cannot be calculated
|
Cannot be calculated
|
0.921
|
|
Others†
|
0.80
|
0.29–2.19
|
0.659
|
Cannot be calculated
|
Cannot be calculated
|
0.925
|
|
Prior chemotherapy regimens
|
|
1
|
1 (ref)
| | |
1 (ref)
| | |
|
2
|
0.60
|
0.27–1.35
|
0.219
|
0.45
|
0.07–2.97
|
0.405
|
|
≥ 3
|
1.25
|
0.60–2.60
|
0.551
|
2.20
|
0.42–11.42
|
0.349
|
|
Multivariate analysis
|
|
Group
|
|
Reduced dose rate group
|
1 (ref)
| | | | | |
|
Conventional dose rate group
|
2.38
|
1.02–5.54
|
0.045
| | | |
|
Total dose (Gy)
|
1.40
|
1.07–1.85
|
0.016
| | | |
|
Daily dose (Gy)
|
0.24
|
0.07–0.83
|
0.025
| | | |
|
Cancer type
|
|
ALL
|
1 (ref)
| | | | | |
|
AML
|
1.69
|
0.83–3.42
|
0.146
| | | |
|
Others
|
1.41
|
0.56–3.52
|
0.463
| | | |
- *other: cytarabine, fludarabine, etoposide † others: cytarabine/fludaraibine, busulfan/fludarabine/etoposide, melphalan, melphalan/fludarabine, thiotepa
